Phaxiam Therapeutics

The NASDAQ Biotech Index is down by nearly 27% since the last peak, the IPO window is virtually shut, there is diminished appetite for secondary offerings, the situation has been made worse by the col

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Busy Moderna Inks Gene-Editing Pact Wit

Rare diseases are becoming increasingly important to French biotech firms, as the sector matures with the help of a government push to improve the ecosystem in the country. Orphan drug research could

Rafael Pharmaceuticals, Inc. ’s lead candidate, devimistat, has hit the buffers in two Phase III trials. It has missed the primary endpoint in a Phase III study for first-line metastatic pancreatic ca